Project Grant R01CA311209
Award Date 5/7/26
Completion Date 4/30/31
Dollars Obligated $641K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $542,644 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on developing radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The research leverages a breakthrough discovery identifying...
- Federal Grant Award Summary The National Cancer Institute awarded Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This research project targets the enhancement of neoantigen cancer vaccine efficacy by investigating the mechanisms through which Type 1 Regulatory (TR1) CD4 T cells suppress antitumor immune responses. The research deliverables include scientific studies designed to...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) effective April 1, 2026, through March 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The project, titled "Rational Design of Next-Generation Engineered T Cells for Enhanced Cancer Immunotherapy," focuses on developing improved chimeric antigen receptor (CAR) T cell therapies by enhancing T cell persistence...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $645,185 Project Grant on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate an innovative immunotherapy combination approach for glioblastoma treatment. The research will deliver two primary products: (1) mechanistic studies establishing how long-acting Interleukin-7 (IL-7) combined with oncolytic virus therapy improves CD8+ T cell...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $679,290 Project Grant to the University of California, San Francisco (UCSF) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and translate novel hyperpolarized (HP) carbon-13 dual-agent magnetic resonance imaging (MRI) technologies for improved prostate cancer diagnosis and biopsy guidance. The award, effective April 1, 2026, through March 31, 2031, supports research designed to...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...
- Federal Project Grant Award Summary Emory University received a $402,401 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective May 6, 2026, with a completion date of April 30, 2028. The award supports the development of an 18F-labeled positron emission tomography (PET) imaging agent capable of detecting and measuring isocitrate dehydrogenase 1 mutant (IDH1-R132H) expression in gliomas. This exploratory...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $160,093 Project Grant effective May 1, 2026, through April 30, 2028, under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports research investigating perceptions and informational needs regarding risk-based prostate cancer screening among screening-eligible men. The research addresses disparities in prostate-specific antigen (PSA) screening practices, particularly among...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research into novel dendritic cell-based immunotherapy for solid tumors. The project will deliver mechanistic characterization and preclinical development of AB7H3-TLR4 chimeric antigen receptor (CAR) dendritic cells (DCs)—engineered immune cells designed to overcome tumor immune...